Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing ® and Ornibel Premium ® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring

María Ángeles Pérez de la Cruz, Carlos Diez, Sandra Urek, Sonia Matilla, Pedro-Antonio Regidor

Open source

DOI: 10.1080/13625187.2026.2716224
Published: 2026-08-17
Container: The European Journal of Contraception & Reproductive Health Care
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/13625187.2026.2716224,
  title = {Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing
                    <sup>®</sup>
                    and Ornibel Premium
                    <sup>®</sup>
                    (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring},
  author = {María Ángeles Pérez de la Cruz and Carlos Diez and Sandra Urek and Sonia Matilla and Pedro-Antonio Regidor},
  year = {2026},
  journal = {The European Journal of Contraception \&amp; Reproductive Health Care},
  doi = {10.1080/13625187.2026.2716224},
  url = {https://doi.org/10.1080/13625187.2026.2716224}
}

RIS

TY  - JOUR
TI  - Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing
                    <sup>®</sup>
                    and Ornibel Premium
                    <sup>®</sup>
                    (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring
AU  - María Ángeles Pérez de la Cruz
AU  - Carlos Diez
AU  - Sandra Urek
AU  - Sonia Matilla
AU  - Pedro-Antonio Regidor
PY  - 2026
JO  - The European Journal of Contraception &amp; Reproductive Health Care
DO  - 10.1080/13625187.2026.2716224
UR  - https://doi.org/10.1080/13625187.2026.2716224
ER  -

APA

Cruz, M. Á. P. D. L., Diez, C., Urek, S., Matilla, S., & Regidor, P. (2026). Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing ® and Ornibel Premium ® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring. The European Journal of Contraception & Reproductive Health Care. https://doi.org/10.1080/13625187.2026.2716224

Source records

crossref · retrieved 2026-09-26T14:31:01.481Z

Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing <sup>®</sup> and Ornibel Premium <sup>®</sup> (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records